|
Synonyms: Example 10 [WO2014071832] | SAF-189 | SAF-189s
Compound class:
Synthetic organic
Comment: Rufutalkib is the INN for an anaplastic lymphoma kinase (ALK) inhibitor, that was included in WHO INN Proposed List 135 (July 2026). There is a structure match for a compound claimed in patent WO2014071832A1 [2]. Online resources suggest that Fochon Pharmaceutical's lead ALK and ROS proto-oncogene 1 (ROS1) kinase inhibitor SAF-189 is also named foritinib, however this is not a bona fide INN. It is likely that rufutalkib is the proposed INN for SAF-189. SAF-189 is intended as an orally bioavailable anti-tumour agent wit potential to overcome crizotinib resistance [1].
|
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| Anti-proliferative and anti-tumour activities are reported in [2], but we have been unable to locate quantitative data for target kinase inhibitory activity. |